AstraZeneca shares dive after failure of key lung cancer drug trial

Ketan Patel, fund manager at EdenTree Investment Management, tells The Guardian that it is difficult to think of a time when a large-cap pharmaceutical company has suffered such a large setback in share price in one day. He believes that further pressure on chief executive Pascal Soriot is to be expected.

Link

top